Cargando…

Beneficial Effects of Combined AT(1) Receptor/Neprilysin Inhibition (ARNI) Versus AT(1) Receptor Blockade Alone in the Diabetic Eye

PURPOSE: Dysfunction of the renin-angiotensin system (RAS) contributes to pathogenesis of diabetic retinopathy (DR). Yet RAS blockers have only limited beneficial effects on progression of DR in clinical trials. The natriuretic peptide system offsets RAS, so that enhancing the activity of this syste...

Descripción completa

Detalles Bibliográficos
Autores principales:	Prasad, Tuhina, Roksnoer, Lodi C. W., Zhu, Ping, Verma, Amrisha, Li, Yiming, Batenburg, Wendy W., de Vries, René, Danser, A. H. Jan, Li, Qiuhong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Association for Research in Vision and Ophthalmology 2016
Materias:	Physiology and Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5156511/ https://www.ncbi.nlm.nih.gov/pubmed/27951594 http://dx.doi.org/10.1167/iovs.16-20289

Ejemplares similares

From ARB to ARNI in Cardiovascular Control
por: Uijl, Estrellita, et al.
Publicado: (2016)

Angiotensin Receptor-Neprilysin Inhibitor (ARNI) and Cardiac Arrhythmias
por: Sutanto, Henry, et al.
Publicado: (2021)

Angiotensin Receptor-Neprilysin Inhibition (ARNI) in Heart Failure
por: Greenberg, Barry
Publicado: (2020)

Combined Renin Inhibition/(Pro)Renin Receptor Blockade in Diabetic Retinopathy- A Study in Transgenic (mREN2)27 Rats
por: Batenburg, Wendy W., et al.
Publicado: (2014)

LCZ696, an angiotensin receptor neprilysin inhibitor (ARNI): clinical development in heart failure and hypertension
por: Lefkowitz, Martin P
Publicado: (2011)

Effects of Angiotensin Receptor-Neprilysin Inhibitors (ARNIs) on the Glucose and Fat Metabolism Biomarkers Leptin and Fructosamine
por: Ohnewein, Bernhard, et al.
Publicado: (2023)

Expression and cellular localization of the Mas receptor in the adult and developing mouse retina
por: Prasad, Tuhina, et al.
Publicado: (2014)

LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor (ARNI): clinical development in heart failure
por: Lefkowitz, Martin P
Publicado: (2015)

Practical Recommendations for the Use of Angiotensin Receptor-Neprilysin Inhibitors (ARNI) in Heart Failure: Insights from Indian Cardiologists
por: Dalal, Jamshed, et al.
Publicado: (2023)

Real-world experience of angiotensin receptor/neprilysin inhibitor (ARNI) usage in Thailand: a single-center, retrospective analysis
por: Rattanavipanon, Wipharak, et al.
Publicado: (2021)

Efficacy and safety analysis of angiotensin receptor neprilysin inhibition(ARNI)in patients with heart failure: a real-world retrospective study
por: Wang, Xiaobo, et al.
Publicado: (2023)

A clinical experience of Indian patients with heart failure with reduced left ventricular ejection fraction using an angiotensin receptor-neprilysin inhibitor [ARNI] on an outpatient basis
por: Jariwala, Pankaj, et al.
Publicado: (2021)

A novel bispecific molecule delivered by recombinant AAV2 suppresses ocular inflammation and choroidal neovascularization
por: Li, Yiming, et al.
Publicado: (2017)

Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial
por: Wachter, Rolf, et al.
Publicado: (2020)

Emerging therapies: The potential roles SGLT2 inhibitors, GLP1 agonists, and ARNI therapy for ARNI pulmonary hypertension
por: King, Nicholas E., et al.
Publicado: (2022)

Monitoring the Effectiveness and Safety of ARNI vs. Angiotensin Receptor Blocker by Frailty Status
por: Kim, Dae, et al.
Publicado: (2021)

Angiotensin receptor blocker neprilysin inhibitors
por: Usuda, Daisuke, et al.
Publicado: (2021)

Angiotensin receptor-neprilysin inhibitors and cardiac remodeling
por: Ryazanov, A.S., et al.
Publicado: (2023)

My gratitude for Arny's friendship with me
por: Õmura, Satoshi
Publicado: (2021)

Insulinotropic Effects of Neprilysin and/or Angiotensin Receptor Inhibition in Mice
por: Esser, Nathalie, et al.
Publicado: (2022)

Amyloid β peptides overexpression in retinal pigment epithelial cells via AAV-mediated gene transfer mimics AMD-like pathology in mice
por: Prasad, Tuhina, et al.
Publicado: (2017)

ANGIOTENSIN (1-7) EXPRESSING LACTOBACILLUS DOSE-DEPENDENTLY BENEFITS THE GUT-BRAIN AXIS IN AGED RATS
por: Sun, Yi, et al.
Publicado: (2019)

Can ARNI Prevent Doxorubicin-Induced Cardiotoxicity?
por: Özgür Barış, Veysel, et al.
Publicado: (2022)

A paean to Arnie Levine on the occasion of his 80th birthday
por: Hinds, Philip W
Publicado: (2019)

Actions of Novel Angiotensin Receptor Blocking Drugs, Bisartans, Relevant for COVID-19 Therapy: Biased Agonism at Angiotensin Receptors and the Beneficial Effects of Neprilysin in the Renin Angiotensin System
por: Moore, Graham J., et al.
Publicado: (2022)

Expression of Human ACE2 in Lactobacillus and Beneficial Effects in Diabetic Retinopathy in Mice
por: Verma, Amrisha, et al.
Publicado: (2019)

Expression of Human ACE2 in Lactobacillus and Beneficial Effects in Diabetic Retinopathy in Mice
por: Verma, Amrisha, et al.
Publicado: (2020)

Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor
por: Dargad, Ramesh R., et al.
Publicado: (2018)

Narrative review in the current role of angiotensin receptor-neprilysin inhibitors
por: Cruz Rodriguez, Jose B., et al.
Publicado: (2021)

Acute Tubular Necrosis Associated with Angiotensin Receptor-neprilysin Inhibitor
por: Kim, Moo Jun, et al.
Publicado: (2021)

Angiotensin receptor-neprilysin inhibitor improves coronary collateral perfusion
por: Li, Kangbo, et al.
Publicado: (2023)

Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)
por: McMurray, John J. V., et al.
Publicado: (2013)

Neprilysin-dependent neuropeptide Y cleavage in the liver promotes fibrosis by blocking NPY-receptor 1
por: Ortiz, Cristina, et al.
Publicado: (2023)

ARNi: A Novel Approach to Counteract Cardiovascular Diseases
por: Volpe, Massimo, et al.
Publicado: (2019)

Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond
por: Singh, Jagdeep SS, et al.
Publicado: (2015)

Getting the “Right” Perspective on Angiotensin Receptor–Neprilysin Inhibition in Heart Failure
por: Verbrugge, Frederik H., et al.
Publicado: (2020)

Efficacy of angiotensin receptor neprilysin inhibitor in Asian patients with refractory hypertension
por: Li, Wanjing, et al.
Publicado: (2022)

Editorial for “Biointelligent manufacturing in Memorium of Arnold (Arny) L. Demain”
por: Gao, Qiang, et al.
Publicado: (2022)

Transient Receptor Potential Channels, Natriuretic Peptides, and Angiotensin Receptor-Neprilysin Inhibitors in Patients With Heart Failure
por: Ding, Kun, et al.
Publicado: (2022)

Effects of the Angiotensin‐Receptor Neprilysin Inhibitor on Cardiac Reverse Remodeling: Meta‐Analysis
por: Wang, Yiwen, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vs657q4rs84ius757o6qpauq4v